News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,273 Results
Type
Article (87413)
Company Profile (739)
Press Release (770103)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232768)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91175)
Employer Resources (205)
FDA (18253)
Job Trends (17422)
News (396850)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (120)
Alliances (56794)
ALS (153)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (312)
Approvals (18366)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (538)
Cancer (4275)
Cardiovascular disease (301)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (760)
Cervical cancer (29)
Clinical research (76103)
Collaboration (1603)
Company closure (4)
Compensation (990)
Complete response letters (64)
COVID-19 (2927)
CRISPR (85)
C-suite (732)
Cystic fibrosis (143)
Data (5407)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (340)
Diagnostics (6976)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (197)
Earnings (97996)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132799)
Executive appointments (824)
FDA (20617)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1269)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (931)
Government (5323)
Grass and pollen (4)
Guidances (276)
Healthcare (20777)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (80)
Infectious disease (3146)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (582)
Lymphoma (331)
Machine learning (41)
Management (66)
Manufacturing (714)
MASH (159)
Medical device (14421)
Medtech (14451)
Mergers & acquisitions (22742)
Metabolic disorders (1062)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (79)
Neuroscience (2891)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (520)
Opinion (325)
Ovarian cancer (150)
Pain (153)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (33)
Patents (394)
Patient recruitment (414)
Peanut (56)
People (66277)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23595)
Phase 2 (33119)
Phase 3 (24813)
Pipeline (4281)
Policy (283)
Postmarket research (3544)
Preclinical (10586)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (278)
Rare diseases (792)
Real estate (7422)
Recruiting (80)
Regulatory (28227)
Reports (63)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (998)
Venture capital (91)
Weight loss (338)
Women's health (71)
Worklife (22)
Date
Last 7 days (472)
Last 30 days (1656)
Last 365 days (25233)
2026 (2379)
2025 (25544)
2024 (34032)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51120)
Australia (9002)
California (9720)
Canada (2473)
China (1055)
Colorado (306)
Connecticut (389)
Delaware (295)
Europe (116899)
Florida (1256)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (652)
India (56)
Indiana (445)
Iowa (21)
Japan (338)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1256)
Massachusetts (7303)
Michigan (244)
Minnesota (452)
Mississippi (5)
Missouri (78)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2549)
New Mexico (29)
New York (2550)
North Carolina (1410)
North Dakota (9)
Northern California (4770)
Ohio (257)
Oklahoma (18)
Oregon (51)
Pennsylvania (1869)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3751)
Tennessee (58)
Texas (1358)
United States (33779)
Utah (209)
Vermont (1)
Virginia (168)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (82)
858,273 Results for "dren bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications.
December 15, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
December 16, 2025
·
4 min read
Press Releases
Dren Bio Receives Prestigious 2025 Prix Galien USA Award for Best Biotech Startup
November 4, 2025
·
3 min read
Collaboration
Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
July 25, 2024
·
2 min read
·
Tristan Manalac
I&I
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.
March 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
March 20, 2025
·
7 min read
Business
Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer
Dren Bio, Inc. , today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.
October 30, 2023
·
3 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
January 27, 2026
·
2 min read
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
·
3 min read
·
Dan Samorodnitsky
1 of 85,828
Next
